Clinical-stage biotechnology company Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) has appointed finance and commercial expert Hamish George as chief financial officer (CFO), effective September 1, 2024.
The company’s board and management team look forward to leveraging George’s expertise in the biotechnology and healthcare sector as the company advances its extensive clinical trial pathway utilising TRP-8802 (oral psilocybin) and TRP-8803 (IV-infused psilocin).
Finance and commercial experience
George is a director at Bio101 Financial Advisory, a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector.
The new CFO has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad, and currently serves as CFO and company secretary for several ASX-listed, private companies and not-for-profits.
Non-executive chairman Mark Davies said: “On behalf of the board, I would like to take this opportunity to welcome Hamish to the company.
"As Tryp further establishes itself as a leading ASX-listed drug developer, the board has made the strategic decision to align its resources accordingly and to this end, we look forward to working with someone of Hamish’s calibre to further solidify our positioning.”
George holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.
O’Neill thanked for contribution
As part of the appointment, previous Tryp CFO Jim O’Neill has resigned and the company thanks him for his service.
Tryp said that O’Neill had performed his role as CFO admirably during his tenure and provided extensive expertise to management in the lead-up to the company’s listing on the Australian Securities Exchange in May 2024.
He also provided wide-ranging support to advance the transition of roles to Hamish George during August 2024, enabling him to be fully engaged as CFO from September 1, 2024.
Davies added: “I would also like to thank Jim O’Neill for his contribution to the company in the recent years.
"As CFO over the last three years, Jim has been instrumental in Tryp’s development. He also provided extensive knowledge and support in the company’s transition to the ASX.
"The board and management wish him well for his future endeavours.”